Quarterly Activities/Appendix 4C Cash Flow Report

• Further promising developments from the ongoing ACCENT trial of narmafotinib in metastatic pancreatic cancer
• Ethics approval obtained in Australia for the new trial of narmafotinib, investigating a combination with the chemotherapy FOLFIRINOX
• A key patent protecting narmafotinib has been allowed by the US Patent and Trademarks Office

Amplia Therapeutics Ltd has reported further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and released its Appendix 4C Cash Flow Report for the quarter ending 30 September 2025. The company continues to make significant strides in the clinical development of its best-in-class FAK inhibitor, narmafotinib, for the treatment of metastatic pancreatic cancer. The ACCENT clinical trial, which investigates narmafotinib in combination with standard chemotherapies, has recorded additional confirmed partial responses, bringing the total objective response rate to 33%. Interim data from the trial also indicated a median progression-free survival of 7.6 months, notably higher than the 5.5 months observed with chemotherapy alone. Amplia has also received ethics approval in Australia for a new Phase 1b/2a clinical trial combining narmafotinib with FOLFIRINOX chemotherapy, and the first participants have already started dosing. On the regulatory front, the company has secured a key patent covering the specific salt and crystal form of narmafotinib, ensuring its intellectual property remains safeguarded. Amplia finished the September 2025 quarter with a cash position of $29.2 million, which was further boosted by a $27.5 million capital raise and a $3.8 million R&D tax incentive refund, providing funding into 2027.

As trials mature and further data become available, Amplia remains optimistic about improving outcomes for pancreatic cancer patients through innovative combination therapies. Business development and partnering discussions have advanced in recent months with a number of potential partners and collaborators showing interest in the developing dataset.